Log in

NYSE:PFE - Pfizer Stock Price, Forecast & News

$33.42
-0.68 (-1.99 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$32.53
Now: $33.42
$33.94
50-Day Range
$33.93
MA: $38.02
$40.71
52-Week Range
$32.53
Now: $33.42
$44.56
Volume62.67 million shs
Average Volume26.53 million shs
Market Capitalization$184.95 billion
P/E Ratio11.64
Dividend Yield4.46%
Beta0.67
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.75 billion
Cash Flow$3.71 per share
Book Value$11.03 per share

Profitability

Net Income$16.27 billion

Miscellaneous

Employees92,400
Outstanding Shares5,534,123,000
Market Cap$184.95 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.


Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Monday, December 16th. Shareholders of record on Friday, January 31st will be given a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 dividend on an annualized basis and a yield of 4.55%. The ex-dividend date of this dividend is Thursday, January 30th. This is a boost from Pfizer's previous quarterly dividend of $0.36. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its board has approved a stock repurchase plan on Friday, December 14th 2018, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy up to 3.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its earnings results on Tuesday, January, 28th. The biopharmaceutical company reported $0.55 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.57 by $0.02. The biopharmaceutical company had revenue of $12.69 billion for the quarter, compared to the consensus estimate of $12.73 billion. Pfizer had a return on equity of 27.23% and a net margin of 31.44%. Pfizer's revenue for the quarter was down 9.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY20 earnings guidance on Tuesday, January, 28th. The company provided earnings per share guidance of $2.82-$2.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.72. The company issued revenue guidance of $48.5-$50.5 billion, compared to the consensus revenue estimate of $47.44 billion.

What price target have analysts set for PFE?

12 brokerages have issued 1-year price targets for Pfizer's shares. Their forecasts range from $36.00 to $53.00. On average, they anticipate Pfizer's stock price to reach $41.66 in the next year. This suggests a possible upside of 24.7% from the stock's current price. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

Has Pfizer been receiving favorable news coverage?

Press coverage about PFE stock has trended very negative recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pfizer earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for Pfizer.

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 61,030,000 shares, an increase of 7.1% from the January 30th total of 56,970,000 shares. Based on an average daily trading volume, of 20,840,000 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.1% of the shares of the stock are sold short. View Pfizer's Current Options Chain.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Verizon Communications (VZ), Johnson & Johnson (JNJ), Intel (INTC), General Electric (GE), AbbVie (ABBV), Bank of America (BAC), Exxon Mobil (XOM) and Walt Disney (DIS).

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
  • Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (5.27%), Capital World Investors (3.41%), Geode Capital Management LLC (1.61%), Bank of New York Mellon Corp (1.08%), Massachusetts Financial Services Co. MA (0.94%) and Charles Schwab Investment Management Inc. (0.72%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which institutional investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Massachusetts Financial Services Co. MA, PGGM Investments, California Public Employees Retirement System, LSV Asset Management, CI Investments Inc., PNC Financial Services Group Inc. and KBC Group NV. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

Which institutional investors are buying Pfizer stock?

PFE stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, Renaissance Technologies LLC, Marshall Wace North America L.P., Macquarie Group Ltd., Sanders Capital LLC, Bank of New York Mellon Corp, FIL Ltd and Sound Shore Management Inc. CT. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $33.42.

How big of a company is Pfizer?

Pfizer has a market capitalization of $184.95 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com/.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,345 (Vote Outperform)
Underperform Votes:  966 (Vote Underperform)
Total Votes:  2,311
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel